Scienture's Arbli™ Gains Pediatric Hospital Formulary Wins…

Event summary

Arbli™ (losartan potassium) added to formularies at three leading U.S. pediatric academic medical centers and hospitals.
Arbli™ targets a $219 million U.S. losartan market with 72 million prescriptions annually (IQVIA MAT Apr 2026).
Product designed for pediatric, geriatric, and patients with difficulty swallowing tablets.
Scienture reports sequential increases in wholesale orders.
Arbli™ is the first and only FDA-approved oral liquid formulation of losartan.

The big picture

Scienture's formulary wins for Arbli™ mark a strategic push into the pediatric healthcare sector, where the product's ready-to-use formulation addresses unmet needs in dosing flexibility and patient compliance. The $219 million losartan market presents a significant opportunity, particularly as Scienture leverages high gross margins to drive operating leverage. The broader trend of institutional adoption could set a precedent for other specialty pharmaceutical products targeting niche patient populations.

What we're watching

Market Penetration: Whether Scienture can sustain sequential wholesale order growth amid broader hospital adoption.
Pediatric Focus: How the pediatric hospital market will influence Arbli™'s long-term commercialization strategy.
Competitive Dynamics: The pace at which competitors respond with similar liquid formulations for losartan.